Opthea Limited Sponsored ADR (OPT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Opthea Limited, a biopharmaceutical firm focusing on treatments for retinal diseases like wet AMD, will participate in the UBS Virtual Ophthalmology Day 2024, where its management will engage in a fireside chat and one-on-one meetings with investors. The event will be held on October 2, 2024, and will be webcasted, with Opthea’s CEO Frederic Guerard presenting. The company is currently conducting two pivotal Phase 3 trials for their leading product candidate, sozinibercept, aimed at improving treatment efficacy for retinal diseases when used with existing therapies.
For further insights into OPT stock, check out TipRanks’ Stock Analysis page.